Reference Avram MM, et al. Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend.

Slides:



Advertisements
Similar presentations
Risk Stratification in Renal Care Mary Jane McKendry Vice President, Operations Fresenius Disease Management Optimal Renal Care.
Advertisements

Chapter 7: Pediatric ESRD 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Chronic Uremic Acidosis Nutritional Effects 2 Hypoalbuminemia Osteomalacia (bone mineral loss) Decreased muscle mass Increased incidence of morbidity and.
ESRD Registry Committee, Korean Society of Nephrology*
Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved. Focus on Dialysis and Kidney Transplant (Relates to.
This Power Point presentation belongs to the Danish Renal Registry, which owns the copyright. It can be freely used for non-commercial study and educational.
The mortality associated with body size and muscle mass, fat mass and abdominal obesity in patients receiving hemodialysis Date: 2012/12/21 實習生:余萍 指導老師:蕭佩珍營養師.
Impact of Preoperative Renal Dysfunction in Patients Undergoing Off- pump vs On-pump Coronary Artery Bypass.
Chapter 3: Clinical Indicators and Preventive Care 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Chapter 12: USRDS Special Study Center on Transition of Care in CKD 2014 ANNUAL DATA REPORT VOLUME 1: CHRONIC KIDNEY DISEASE.
Dialysis Facility Compare Valarie Ashby Co-Managing Director UM-KECC.
Vol 2 Figure 1.1 Trends in the number of incident cases of ESRD, in thousands, by modality, in the U.S. population, Data Source: Reference.
Chapter 5: Mortality 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Chapter i: Introduction 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Lesley Stevens MD Tufts-New England Medical Center
Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.
APPENDIX 1. D-1 New cases of diagnosed diabetes D-2.1 All cause mortality* D-2.2 Cardiovascular disease deaths* D-3 Diabetes death rate, multiple cause.
Approach to Advanced Kidney Disease Management in the Elderly Source: Schell JO, Germain MJ, Finkelstein FO, et al. An integrative approach to advanced.
Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.
Hemoglobin A 1c in Hemodialysis Patients Source: Ix JH. Hemoglobin A1c in hemodialysis patients: Should one size fit all? Clin J Am Soc Nephrol. 2010;5:1539–1541.
Health Care Costs Associated with Chronic Kidney Disease in Patients with Type II Diabetes Zita Shiue, MD Internal Medicine, R3 Chief of Medicine Conference.
Outcome of patients started on PD as first line therapy, Saira Usama, Jamal S. Alwakeel, Ahmad H. Mitwalli, Abdulkareem Alsuwaida, Akram Askar, King Khalid.
Peritoneal Dialysis for Elderly Patients: A Review Source: Tesar V. Peritoneal dialysis in the elderly—is its underutilization justified? Nephrol Dial.
James Heaf Herlev Hospital University of Copenhagen
CHRONIC KIDNEY DISEASE National Healthcare Quality and Disparities Report Chartbook on Effective Treatment.
Dialysis: outcome and complications. Introduction Outcomes – 20%+ of dialysis patients die each year, 3YS diabetics ~50% Technical complications –PD –Haemo.
Primary Article Rachel Knepp (Article 1) Pecovnik-Balon, B., Jakopin, E., Bevc, S., Knehtl, M., & Gorenjak, M. (2009). Vitamin D as a novel nontraditional.
Al wakeel J, Bayoumi M, Al Ghonaim M, Al Harbi A, Al Swaida A, Mashraqy A.
Review of literature and report of experience with erythropoietin in ESRD populations Summary to FDA Cardio Renal Committee J. Michael Lazarus, M.D. CMO.
Vascular access for haemodialysis in Scotland Andrew Henderson, Keith Simpson, Gordon Prescott, Joanne Boyd and Alison Severn, on behalf of the Scottish.
ANZDATA Registry Annual Report 2013 Philip Clayton CHAPTER 9 KIDNEY DONATION 2013 Annual Report - 36th Edition PAEDIATRIC CHAPTER 11.
Chapter 5 Peritoneal Dialysis 2014 ANZDATA Registry 37th Annual Report Data to 31-Dec-2013 ANZDATA gratefully acknowledges the contributions of the Peritoneal.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 8: Pediatric ESRD.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 6: Mortality.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 3: Clinical Indicators and Preventive Care.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 5: Hospitalization.
CHAPTER 2 DIALYSIS IN MALAYSIA Goh Bak Leong Lim Yam Ngo Ong Loke Meng Ghazali Ahmad Lee Day Guat Source: 20 th MDTR Report 2012, NRR.
Kidney disease burden and available Renal transplantation and Dialysis services in India Dr. Sham Sunder.
Medical Technology and Practice Patterns Institute 4733 Bethesda Ave., Suite #510 Bethesda, MD Phone: Fax: Comparison of.
The balANZ Trial. Source Johnson DW, Clarke M, Wilson V, et al. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Similar Outcomes With Hemodialysis and Peritoneal.
The RAVE Study Renal Athersosclerotic Revascularization Evaluation Reference Tobe SW, Atri M, Perkins N, et al. Renal Athersosclerotic revascularization.
Chronic Haemodialysis therapy in octogenarians with ESRF: demographics and outcomes from a single centre in England Dr Punit Yadav Dr Jyoti Baharani.
Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.
Am J Kidney Dis. 2014;63(6): R3 박세정 /prof. 이태원 Comparative Effectiveness of Early Versus Conventional Timing of Dialysis Initiation in Advanced.
KT AS A QUALITY INDICATOR OF HAEMODIALYSIS ADEQUACY: COMPARISON OF KT/V, KT ACCORDING TO THE GENDER AND BODY SURFACE AREA The dialysis dose monitored with.
Long Term Peritoneal Dialysis In Children – Frequent Complications Conclusions: Peritoneal Dialysis is the method of choice for pediatric patients, with.
Is it possible to predict New Onset Diabetes After Transplantation (NODAT) in renal recipients using epidemiological data alone? Background NODAT is an.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Preemptive Kidney Transplant (PKT) – the Optimal Therapy in ESRD Reference: Connie L. Davis. Preemptive transplantation and the transplant first initiative.
The STARRT Trial Source: Piwko C, Vicente C, Marra L, et al. The STARRT trial: a cost comparison of optimal vs sub-optimal initiation of dialysis in Canada.
USRDS USRDS 2002 adr Incident counts by initial modality figure 7.1 patients age 19 years & younger.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
1. The STRATA Study. Kidney Transplant 1. The STRATA Study (Study of Transplant-Related Anemia Treated with Aranesp) Source Bloom RD, Bolin P, Gandra.
Figure 3.1 ESRD clinical indicators, CROWNWeb data, December 2015
Residual Kidney Function Decline and Mortality
2016 Annual Data Report, Vol 2, ESRD, Ch 6
First-year death rates by modality figure 8
The HEMO Study Hemodialysis (HEMO) Study Reference
The ADEMEX Trial Adequacy of PD in Mexico Reference
The IDEAL Study Reference
HEIGHT-AGE-SEX SPECIFIC BODY MASS INDEX IN CHILDREN WITH END STAGE RENAL DISEASE - SINGLE CENTER EXPERIENCE 1 Fundeni Clinical Institute, Bucharest, Romania.
The CANUSA Trial Reference
Mycobacterium tuberculosis infection of end-stage renal disease patients in Taiwan: a nationwide longitudinal study  S.-Y. Li, T.-J. Chen, K.-W. Chung,
CHAPTER 5 Paediatric Renal Replacement Therapy
Volume 2: End-Stage Renal Disease
A Six-hour Hemodialysis Without a Significant Increase in Dialysis Dose, as Judged by Kt/V, Can Reduce the Dosage of Erythropoietin Department of Kidney.
Mortality caused by sepsis in patients with end-stage renal disease compared with the general population  Mark J. Sarnak, Bertrand L. Jaber  Kidney International 
Volume 64, Issue 3, Pages (September 2003)
The Centers for Medicare and Medicaid Services (CMS) and the Kidney Care Quality Alliance (KCQA) ultrafiltration (UF) rate measure specifications and selection.
Presentation transcript:

Reference Avram MM, et al. Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int. 2003;64(Suppl.87): S6–S11. Hemoglobin Predicts Long-term Survival in Dialysis Patients Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin

Background Patients on dialysis have a higher mortality rate than the general population. A very common complication of uremia in dialysis patients is anemia. There are huge benefits of anemia correction with human recombinant erythropoietin (rHuEPO). However, the ideal levels of hemoglobin in dialysis patients remain blurred. In this study, the association of hemoglobin at initiation of trial is done with long-term survival in hemodialysis and peritoneal dialysis

Aim To evaluate the association of enrollment hemoglobin with long-term survival in hemodialysis (HD) and peritoneal dialysis (PD) patients and the inter-relationship between prealbumin and anemia and their impact on mortality.

Method Study population: 529 HD and 326 PD patients were enrolled in this trial, which was initiated in 1987 and continued till The demographical and clinical data were collected which included age, race, sex, gender, diabetic status, etiology of end-stage renal disease (ESRD), total months of dialysis therapy initiation and seropositive to HIV. Treatment regimen: The HD patients were treated with volumetric ultrafiltration control and dialysate (bicarbonate based). Cellulose-based membranes (predominantly cellulose acetate and cellulose triacetate) were used prior to 1998 for more than 95% of all treatments. Thereafter, all patients were switched to polysulfone membranes. Prior to 1992, most patients were treated with continuous ambulatory peritoneal dialysis and received four 2-L LVP solution exchanges per day. After 1992, the PD prescription was to achieve a weekly target of 1.7 Kt/V, which was further increased to 2.1 Kt/V.

Results In the HD patients, causes of ESRD were listed as follows: diabetes (40%), hypertension (31%), glomerulonephritis (11%), polycystic kidney disease (4%), obstruction (2%) and unknown (11%). A total of 54.6% HD patients have died. Patients were stratified by hemoglobin level ≥12 g/dl and more than 12 g/dl. Survival of patients with initial hemoglobin more than 12 g/dl was better than that of patients with hemoglobin less than 12 g/dl. However, a subgroup analysis showed that this was only true in case of non-diabetic patients.

In patients with PD, the causes of ESRD were diabetes (35%), hypertension (30%), glomerulonephritis (9%), polycystic kidney disease (3%), obstruction (3%) and unknown (13%). 54% of the PD patients have died. Peritoneal dialysis patients were grouped by hemoglobin levels: ≥12 and <12 g/dL. The survival of PD patients with enrollment hemoglobin less than 12 g/dl was better than that of patients with hemoglobin more than 12 g/dl. Hemoglobin was weekly correlated to hemoglobin in both HD and PD patients.

Conclusion Hemoglobin levels of more than 12 g/dl had better survival levels than patients with lower hemoglobin levels. Hence it can be concluded that hemoglobin levels influence the survival of patients in HD and PD. Higher the hemoglobin levels, better the survival rate in patients with HD and PD.